Answers are grounded in this paper and cite their sources.
In recent years, castration resistant prostate cancer patients therapeutic landscape has dramatically changed. The use of taxane-based chemotherapy, new generation hormone therapy, an immunotherapeutic agent Sipuleucel-T, an alpha-emitter Radium-223, and recently PARP-inhibitors has provided a consistent benefit in terms of survival and quality of life.
No takes yet. Share an insight, caveat, or question.
Ungaro et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: